PeopleBio

피플바이오 · 304840

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$19.4M (₩26.8B)

Overview

PeopleBio develops blood-based diagnostic tests designed to detect Alzheimer's disease at an early stage, before severe cognitive decline sets in.

Its products are intended for use in clinical and research settings where identifying the disease's biological markers, particularly amyloid proteins in the brain, is needed to guide treatment decisions. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, and its work centers on a single disease area: the early diagnosis of Alzheimer's through biomarker testing.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$2.1M

▼ −23.6% YoY

Operating profit · FY2025

−US$6.1M

Loss narrowed

Net income · FY2025

−US$12.3M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$3.2M(₩4.5B)	US$2.7M(₩3.7B)	US$2.1M(₩2.9B)
Operating profit	−US$11M(−₩15.2B)	−US$8.3M(−₩11.5B)	−US$6.1M(−₩8.4B)
Net income	−US$976.5K(−₩1.3B)	−US$912.7K(−₩1.3B)	−US$12.3M(−₩16.9B)

Revenue

FY2023US$3.2M
FY2024US$2.7M
FY2025US$2.1M

Operating profit

FY2023−US$11M
FY2024−US$8.3M
FY2025−US$6.1M

Net income

FY2023−US$976.5K
FY2024−US$912.7K
FY2025−US$12.3M

Key ratios (FY2025)

ROE

-59.2%

Debt/Eq

55.8%

Op. margin

-293.9%

Net margin

-594.2%

Rev. YoY

▼ −23.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?